X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs DIVIS LABORATORIES - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD DIVIS LABORATORIES ALEMBIC LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 56.2 32.5 173.3% View Chart
P/BV x 2.3 5.8 40.4% View Chart
Dividend Yield % 0.4 0.9 50.9%  

Financials

 ALEMBIC LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
DIVIS LABORATORIES
Mar-17
ALEMBIC LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs721,222 5.9%   
Low Rs34784 4.3%   
Sales per share (Unadj.) Rs4.7153.1 3.1%  
Earnings per share (Unadj.) Rs6.139.9 15.3%  
Cash flow per share (Unadj.) Rs6.244.6 14.0%  
Dividends per share (Unadj.) Rs0.2010.00 2.0%  
Dividend yield (eoy) %0.41.0 37.9%  
Book value per share (Unadj.) Rs40.7201.8 20.1%  
Shares outstanding (eoy) m267.03265.47 100.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.36.6 171.9%   
Avg P/E ratio x8.725.1 34.5%  
P/CF ratio (eoy) x8.522.5 37.7%  
Price / Book Value ratio x1.35.0 26.2%  
Dividend payout %3.325.0 13.1%   
Avg Mkt Cap Rs m14,139266,266 5.3%   
No. of employees `000NA9.7 0.0%   
Total wages/salary Rs m2074,687 4.4%   
Avg. sales/employee Rs ThNM4,175.0-  
Avg. wages/employee Rs ThNM481.5-  
Avg. net profit/employee Rs ThNM1,089.3-  
INCOME DATA
Net Sales Rs m1,25540,643 3.1%  
Other income Rs m370749 49.4%   
Total revenues Rs m1,62541,392 3.9%   
Gross profit Rs m11114,460 0.8%  
Depreciation Rs m381,233 3.1%   
Interest Rs m223 7.5%   
Profit before tax Rs m44213,953 3.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m243,349 0.7%   
Profit after tax Rs m1,63010,604 15.4%  
Gross profit margin %8.935.6 24.9%  
Effective tax rate %5.424.0 22.6%   
Net profit margin %129.826.1 497.7%  
BALANCE SHEET DATA
Current assets Rs m1,86740,105 4.7%   
Current liabilities Rs m5916,595 9.0%   
Net working cap to sales %101.682.5 123.3%  
Current ratio x3.26.1 51.9%  
Inventory Days Days94119 79.5%  
Debtors Days Days7481 91.1%  
Net fixed assets Rs m1,79119,995 9.0%   
Share capital Rs m534531 100.6%   
"Free" reserves Rs m10,32453,043 19.5%   
Net worth Rs m10,85853,574 20.3%   
Long term debt Rs m410-   
Total assets Rs m11,59161,585 18.8%  
Interest coverage x260.9618.4 42.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.7 16.4%   
Return on assets %14.117.3 81.6%  
Return on equity %15.019.8 75.8%  
Return on capital %15.226.1 58.2%  
Exports to sales %1.50-   
Imports to sales %21.025.2 83.1%   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m26310,259 2.6%   
Fx inflow Rs m1935,384 0.1%   
Fx outflow Rs m26410,399 2.5%   
Net fx Rs m-24424,985 -1.0%   
CASH FLOW
From Operations Rs m23611,493 2.1%  
From Investments Rs m-224-11,372 2.0%  
From Financial Activity Rs m-27-93 28.6%  
Net Cashflow Rs m-1528 -52.1%  

Share Holding

Indian Promoters % 64.0 52.0 123.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.8 1.7%  
FIIs % 9.7 19.0 51.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 17.2 151.7%  
Shareholders   54,701 31,796 172.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   FRESENIUS KABI ONCO.  ELDER PHARMA  SUVEN LIFE  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Aug 17, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 5-YR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS